Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

591 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.
Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Volberding PA. Yeni PG, et al. Among authors: vella s. JAMA. 2002 Jul 10;288(2):222-35. doi: 10.1001/jama.288.2.222. JAMA. 2002. PMID: 12095387 Review.
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.
Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA; International AIDS Society-USA panel. Hammer SM, et al. Among authors: vella s. JAMA. 2006 Aug 16;296(7):827-43. doi: 10.1001/jama.296.7.827. JAMA. 2006. PMID: 16905788
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel.
Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA; International AIDS Society--USA Panel. Hammer SM, et al. Among authors: vella s. Top HIV Med. 2006 Aug-Sep;14(3):827-43. Top HIV Med. 2006. PMID: 17016878
Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs.
Katlama C, Deeks SG, Autran B, Martinez-Picado J, van Lunzen J, Rouzioux C, Miller M, Vella S, Schmitz JE, Ahlers J, Richman DD, Sekaly RP. Katlama C, et al. Among authors: vella s. Lancet. 2013 Jun 15;381(9883):2109-17. doi: 10.1016/S0140-6736(13)60104-X. Epub 2013 Mar 29. Lancet. 2013. PMID: 23541541 Free PMC article. Review.
A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease.
Fischl MA, Ribaudo HJ, Collier AC, Erice A, Giuliano M, Dehlinger M, Eron JJ Jr, Saag MS, Hammer SM, Vella S, Morse GD, Feinberg JE, Demeter LM, Eshleman SH; Adult AIDS Clinical Trials Group 388 Study Team. Fischl MA, et al. Among authors: vella s. J Infect Dis. 2003 Sep 1;188(5):625-34. doi: 10.1086/377311. Epub 2003 Aug 15. J Infect Dis. 2003. PMID: 12934177 Clinical Trial.
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.
Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, Dubé MP, Fischl MA, Pollard RB, Delapenha R, Gedeon L, van der Horst C, Murphy RL, Becker MI, D'Aquila RT, Vella S, Merigan TC, Hirsch MS; AIDS Clinical Trials Group 384 Team. Robbins GK, et al. Among authors: vella s. N Engl J Med. 2003 Dec 11;349(24):2293-303. doi: 10.1056/NEJMoa030264. N Engl J Med. 2003. PMID: 14668455 Free PMC article. Clinical Trial.
2021 update to HIV-TRePS: a highly flexible and accurate system for the prediction of treatment response from incomplete baseline information in different healthcare settings.
Revell AD, Wang D, Perez-Elias MJ, Wood R, Cogill D, Tempelman H, Hamers RL, Reiss P, van Sighem A, Rehm CA, Agan B, Alvarez-Uria G, Montaner JSG, Lane HC, Larder BA; RDI study group. Revell AD, et al. J Antimicrob Chemother. 2021 Jun 18;76(7):1898-1906. doi: 10.1093/jac/dkab078. J Antimicrob Chemother. 2021. PMID: 33792714 Free PMC article.
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART.
Lambert-Niclot S, George EC, Pozniak A, White E, Schwimmer C, Jessen H, Johnson M, Dunn D, Perno CF, Clotet B, Plettenberg A, Blaxhult A, Palmisano L, Wittkop L, Calvez V, Marcelin AG, Raffi F; NEAT 001/ANRS 143 Study Group. Lambert-Niclot S, et al. J Antimicrob Chemother. 2016 Apr;71(4):1056-62. doi: 10.1093/jac/dkv427. Epub 2015 Dec 24. J Antimicrob Chemother. 2016. PMID: 26702926 Free article. Clinical Trial.
591 results